Eloralintide 10mg

Eloralintide Research Peptide | Amylin Receptor Agonist

Eloralintide is one of the most closely followed new compounds in metabolic research. It is a long-acting peptide designed to act on the amylin receptor, which is involved in appetite and satiety signalling. Phase 2 results were published in 2025 and phase 3 studies are now under way.

What Is Eloralintide?

Eloralintide (development code LY3841136) is a synthetic, lipidated peptide based on amylin, a hormone released together with insulin after meals. Earlier amylin-based peptides also act strongly on calcitonin receptors. Eloralintide was designed to be selective for the amylin receptor, with a long duration of action.

Why Researchers Study Eloralintide

• Amylin receptor selectivity, useful for studying amylin signalling on its own.
• A long-acting design, of interest for research on how peptide structure affects duration of action.
• Combination research alongside incretin-based compounds such as tirzepatide.
• A pathway separate from GLP-1, giving another angle on appetite and satiety signalling.

Eloralintide Specifications

Storage and Handling

Keep sealed vials refrigerated at 2 to 8°C and away from light. Vials ship as lyophilised powder.

Ordering Eloralintide Worldwide

Every order ships in plain, discreet packaging with a tracking number. Pay by card or by crypto (BTC or USDT) at checkout. Import rules for research peptides differ by country, so check the rules where you are before you order. See our shipping policy and FAQ for details. For trial data, read our eloralintide clinical trial results guide, or compare eloralintide vs retatrutide.

For research use only. Not for human or veterinary consumption. This product is intended strictly for laboratory research. It is not for diagnostic or therapeutic use. Nothing on this page is medical advice or a therapeutic claim, and no statement here describes an effect of eloralintide in humans.